Growth Hormone Deficiency companies

Companies Dominating the Growth Hormone Deficiency Landscape

The growth hormone deficiency market comprises leading firms that are undertaking various initiatives to strengthen their position in the global market. In this regard, it is reported that leaders such as Novo Nordisk, Pfizer, and Eli Lilly have garnered a significant share of 62%. Besides, firms are leveraging biosimilar expansion, such as those by Pfizer and Sandoz, that reduced prices by 25% to 55% to penetrate emerging nations. Furthermore, long-acting formulations as Novo Nordisk’s weekly injection called NorditropinFlexPro, capture 40% of U.S. new prescriptions, thereby progressing wider market development.

Here is the list of some prominent players in the industry:

Company Name	Country	Market Share
Novo Nordisk	Denmark	30%
Pfizer Inc.	USA	20%
Eli Lilly	USA	18%
Merck KGaA	Germany	10%
Roche	Switzerland	9%
Ferring Pharmaceuticals	Switzerland	xx%
LG Chem	South Korea	xx%
Teva Pharmaceuticals	Israel	xx%
Biocon	India	xx%
GeneScience Pharmaceuticals	China	xx%
Anhui Anke Biotechnology	China	xx%
Dong-A ST	South Korea	xx%
Mitsubishi Tanabe Pharma	Japan	xx%
Lupin	India	xx%
Amgen	USA	xx%
Sando	Germany	xx%
JCR Pharmaceuticals	Japan	xx%
CSL Limited	Australia	xx%
Malayan Pharmaceuticals	Malaysia	xx%
Reliance Life Sciences	India	xx%

Below are the areas covered for each company under the top 15 global manufacturers:

• Company Overview
• Business Strategy
• Key Product Offerings
• Financial Performance
• Key Performance Indicators
• Risk Analysis
• Recent Development
• Regional Presence
• SWOT Analysis